ASLAN Pharmaceuticals

You are now leaving our web site.
I understand
Programs
Discovery
Preclinical
Phase 1
Phase 2
Anticipated Milestones
ASLAN004IL-4/IL-13 Receptor inhibitor
Atopic dermatitis

MAD interim data early 2020

MAD completion 2H 2020

Asthma
ASLAN003DHODH inhibitor
AML
Varlitinib(ASLAN001)Pan-HER inhibitor
Gastric cancer (2nd line)
Neoadjuvant breast cancer
Hepatocellular carcinoma (2nd line)
Biliary tract cancer (1st line)

Discovery Programs

AhR antagonist1
Oncology
1 Aryl hydrocarbon receptor, or AhR, program is being developed in an ASLAN majority-owned joint venture with Bukwang Pharmaceutical Co., Ltd.
Investigator Initiated Trial


ASLAN004

Phase 1

IL-4R / IL-13R inhibitor with the potential to be best-in-class therapy for atopic dermatitis and asthma

Read more about ASLAN004

ASLAN003

Phase 2

Oral DHODH inhibitor with potential to be first-in-class therapy for acute myeloid leukaemia (AML)

Read more about ASLAN003

Varlitinib

Pivotal

Potential to be the first targeted therapy approved for biliary tract cancer

Read more about Varlitinib

AhR antagonist

Discovery

Aryl hydrocarbon receptor (AhR) program being developed in oncology

Read more about AhR antagonist

Therapeutic Areas

We target diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe.

Atopic dermatitis AML (Acute Myeloid Leukemia) BTC (Biliary Tract Cancer)

Atopic dermatitis

Atopic dermatitis is the most common dermatological disease, affecting over 200 million patients worldwide. Up to one-third of adult atopic dermatitis patients are considered moderate-to-severe, for which currently available therapeutics are limited and management is challenging in the majority of cases.

ASLAN004 is a fully human monoclonal antibody that targets the IL-13 receptor α1 subunit, or IL-13Rα1, with potential to be a best-in-class therapy for atopic dermatitis. ASLAN004 is currently undergoing a phase 1 study for the treatment of atopic dermatitis. The SAD portion of the study was completed in the second quarter of 2019. The MAD portion of the study is ongoing with interim data expected in early 2020, and completion expected in the second half of 2020.

AML (Acute Myeloid Leukemia)

The majority of the total AML population have failed on standard of care chemotherapy in AML or do not respond to chemotherapy, which are termed relapsed/refractory. In 2016, the annual incidence of relapsed/refractory patients is approximately 13,000 patients in the United States, 8,000 in Europe, 5,000 in Japan and 24,000 in China. Survival is age-dependent and survival rates are extremely poor for the elderly. The five-year relative survival rate for AML patients aged 19 years and below is 65% but declines to 50% for patients aged 20 to 49 years, and the survival rate for patients aged 65 years or older is only 6%.

The first-line treatment for patients with AML is a combination of aggressive chemotherapies. However, elderly patients with AML are typically ineligible for aggressive treatment regimens due to the significant toxicity associated with these therapies. The survival of these patients is usually less than one year. Over the past two decades, many compounds have been evaluated in AML patients, however, only three targeted drugs have been approved. Furthermore, these drugs target relatively small subsets of patients, leaving a significant unmet need.

A potent inhibitor of DHODH, ASLAN003 has a potentially differentiated safety profile and may be applicable in broad range of AML patients. Ex-vivo and in-vivo data has shown promising efficacy of ASLAN003 in AML. ASLAN has completed a dose escalation trial testing ASLAN003 as a monotherapy in refractory AML patients, and our observed signs of clinical activity and tolerance leads us to believe that ASLAN003 could be applicable in a broad range of AML patients.

BTC (Biliary Tract Cancer)

In 2016 the prevalence of biliary tract cancer (BTC) was over 200,000 patients in Asia, compared to approximately 12,600 in the United States. BTC has a five-year survival rate of less than 10% and there has been little improvement in prognosis or treatment outcomes over the last two decades.

Though biliary tract cancer is considered to be a subset of liver cancer, therapies approved for liver cancer are not approved for biliary tract cancer. There are no therapies approved for BTC in the United States. Approximately 35% of patients undergo surgical resection, but recurrence is common, with the disease returning in 50% to 60% of patients.

ASLAN has demonstrated that varlitinib shows clinical activity in BTC where HER family expression is known to be high. While specific pathways driving BTC have not been identified, recent data from Japan and China show that approximately 70% of BTC tumours exhibit HER family overexpression, with HER4 expressed most widely.

Varlitinib is the only pan-HER being developed in BTC, and is currently being tested in first-line BTC. ASLAN has reported positive phase 1b data in first-line BTC that demonstrates increased activity over standard of care.

[1] As of 2016, based on Edison Investment Research, “Novel treatments for worldwide unmet needs,” dated November 8, 2017, surveying Randi et al. (2008), Epidemiology of biliary tract cancers: an update; Bridgewater et al. (2014), Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.